Lisa R. Gerak
Affiliations: | Pharmacology | University of Tennessee Health Science Center, Memphis, TN, United States |
Area:
Behavioral pharmacologyGoogle:
"Lisa Gerak"Mean distance: 17.14 (cluster 19) | S | N | B | C | P |
Cross-listing: Chemistry Tree
Parents
Sign in to add mentor
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| France CP, Ahern G, Averick S, et al. (2020) Countermeasures for preventing and treating opioid overdose. Clinical Pharmacology and Therapeutics |
| Mada S, Gerak LR, Soyer A, et al. (2020) Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy µ opioid receptor agonist and a δ opioid receptor antagonist. Psychopharmacology |
| Maguire DR, Gerak LR, Sanchez JJ, et al. (2020) Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology |
| Maguire DR, Gerak LR, Cami-Kobeci G, et al. (2019) OREX-1019: a novel treatment for opioid use disorder and relapse prevention. The Journal of Pharmacology and Experimental Therapeutics |
| Gerak LR, Maguire DR, France CP. (2019) Behavioral Pharmacology of Drugs Acting at Mu Opioid Receptors. Handbook of Experimental Pharmacology |
| Gerak LR, Minervini V, Latham E, et al. (2019) Methocinnamox (MCAM) produces long-lasting antagonism of the behavioral effects of µ opioid receptor agonists but not prolonged precipitated withdrawal in rats. The Journal of Pharmacology and Experimental Therapeutics |
| Gerak LR, Weed PF, Maguire DR, et al. (2019) Effects of the synthetic cannabinoid receptor agonist JWH-018 on abuse-related effects of opioids in rhesus monkeys. Drug and Alcohol Dependence. 202: 33-38 |
| Gerak LR, Maguire DR, Woods JH, et al. (2018) Reversal and prevention of the respiratory-depressant effects of heroin by the novel µ opioid receptor antagonist methocinnamox in rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics |
| Maguire DR, Gerak LR, Woods JH, et al. (2018) Long-lasting effects of methocinnamox on heroin self-administration in rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics |
| Gerak LR, Collins GT, Maguire DR, et al. (2018) Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys. Experimental and Clinical Psychopharmacology |